Apollomics (APLM) Competitors $7.64 -0.77 (-9.11%) Closing price 03/28/2025 03:50 PM EasternExtended Trading$7.64 0.00 (0.00%) As of 03/28/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM vs. XLO, ATRA, SCYX, DYAI, FBLG, FBRX, PRLD, MDCX, SRZN, and ELYMShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Xilio Therapeutics (XLO), Atara Biotherapeutics (ATRA), SCYNEXIS (SCYX), Dyadic International (DYAI), FibroBiologics (FBLG), Forte Biosciences (FBRX), Prelude Therapeutics (PRLD), Medicus Pharma (MDCX), Surrozen (SRZN), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Xilio Therapeutics Atara Biotherapeutics SCYNEXIS Dyadic International FibroBiologics Forte Biosciences Prelude Therapeutics Medicus Pharma Surrozen Eliem Therapeutics Apollomics (NASDAQ:APLM) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations. Do analysts rate APLM or XLO? Apollomics presently has a consensus target price of $200.00, suggesting a potential upside of 2,519.52%. Xilio Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 436.19%. Given Apollomics' higher possible upside, research analysts clearly believe Apollomics is more favorable than Xilio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to APLM or XLO? In the previous week, Apollomics had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 4 mentions for Apollomics and 3 mentions for Xilio Therapeutics. Apollomics' average media sentiment score of 0.84 beat Xilio Therapeutics' score of 0.72 indicating that Apollomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in APLM or XLO? 19.1% of Apollomics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in APLM or XLO? Xilio Therapeutics received 8 more outperform votes than Apollomics when rated by MarketBeat users. However, 80.00% of users gave Apollomics an outperform vote while only 75.00% of users gave Xilio Therapeutics an outperform vote. CompanyUnderperformOutperformApollomicsOutperform Votes480.00% Underperform Votes120.00% Xilio TherapeuticsOutperform Votes1275.00% Underperform Votes425.00% Which has better earnings & valuation, APLM or XLO? Xilio Therapeutics has higher revenue and earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApollomics$1.22M6.80-$172.60MN/AN/AXilio Therapeutics$6.34M6.09-$76.40M-$1.28-0.58 Which has more volatility and risk, APLM or XLO? Apollomics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Is APLM or XLO more profitable? Apollomics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ApollomicsN/A N/A N/A Xilio Therapeutics N/A -211.50%-80.31% SummaryApollomics beats Xilio Therapeutics on 8 of the 13 factors compared between the two stocks. Remove Ads Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.30M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E RatioN/A7.2623.5818.74Price / Sales6.80218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book0.166.386.894.23Net Income-$172.60M$142.34M$3.20B$247.47M7 Day Performance-23.62%-5.15%-3.06%-2.29%1 Month Performance15.33%-7.55%1.51%-5.81%1 Year Performance-89.82%-11.06%9.37%-0.96% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics2.5637 of 5 stars$7.64-9.1%$200.00+2,519.5%-89.8%$8.30M$1.22M0.0045Short Interest ↓News CoveragePositive NewsGap UpXLOXilio Therapeutics3.3241 of 5 stars$0.79-0.5%$4.00+409.1%-30.9%$40.68M$6.34M-0.4670Short Interest ↓ATRAAtara Biotherapeutics4.0177 of 5 stars$6.94+4.7%$17.75+155.8%-62.4%$40.66M$128.94M-0.27330SCYXSCYNEXIS1.0819 of 5 stars$1.04flatN/A-32.0%$40.54M$3.75M-1.4160DYAIDyadic International2.27 of 5 stars$1.37-2.8%$6.00+338.0%-18.0%$40.54M$3.36M-5.967Earnings ReportNews CoverageFBLGFibroBiologics2.1468 of 5 stars$1.11flat$13.00+1,071.2%-91.2%$40.41MN/A0.0010Upcoming EarningsNews CoverageFBRXForte Biosciences2.98 of 5 stars$6.32-22.6%$23.58+273.2%+29,345.6%$40.40MN/A-0.395News CoverageGap UpPRLDPrelude Therapeutics2.7576 of 5 stars$0.72+1.3%$4.00+455.6%-83.1%$39.71M$7M-0.40120Insider TradeNews CoveragePositive NewsGap UpMDCXMedicus PharmaN/A$3.26-1.8%$10.00+206.7%N/A$39.57MN/A0.00N/AEarnings ReportGap DownSRZNSurrozen3.4038 of 5 stars$12.00-3.6%$38.50+220.8%-29.9%$39M$10M0.0080Insider TradeNews CoveragePositive NewsGap DownHigh Trading VolumeELYMEliem TherapeuticsN/A$1.30+1.6%N/A-53.3%$38.68MN/A-2.459 Remove Ads Related Companies and Tools Related Companies Xilio Therapeutics Competitors Atara Biotherapeutics Competitors SCYNEXIS Competitors Dyadic International Competitors FibroBiologics Competitors Forte Biosciences Competitors Prelude Therapeutics Competitors Medicus Pharma Competitors Surrozen Competitors Eliem Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLM) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
